ZIDOVUDINE

Post-LOE

zidovudine

Aurobindo Pharma

ANDAORALCAPSULE

Approved

Mar 2006

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

ZIDOVUDINE (zidovudine) by Aurobindo Pharma is nucleoside reverse transcriptase inhibitors [moa]. Approved for human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2006.

Drug data last refreshed 20h ago

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT00000920Phase 1Completed

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

24 enrolled

HIV InfectionsPregnancy

NCT00000671Phase 2Completed

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

750 enrolled

HIV Infections

NCT00000969N/ACompleted

A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy

400 enrolled

HIV Infections

NCT00000672Phase 2Completed

An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex

660 enrolled

HIV Infections

NCT00000862Phase 1Completed

A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women

36 enrolled

HIV InfectionsPregnancy

Worked on ZIDOVUDINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.